SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Maxim
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (18)4/18/2000 2:03:00 PM
From: biowa   of 24
 
Rick,

combination therapy will continue to prevail

I think MMP would agree with you; don't know if you saw this earlier this month:

Maxim Pharmaceuticals Expands Testing of Maxamine in Hepatitis C

siliconinvestor.com

SAN DIEGO--(BW HealthWire)--April 3, 2000--Maxim Pharmaceuticals (AMEX: MMP) (SSE:MAXM) announced the initiation of a clinical study to evaluate the safety of triple-drug therapy incorporating the company's lead drug, Maxamine(R), in patients with chronic hepatitis C infection.

The study will evaluate the safety of treatment with Maxamine in combination with the immunotherapeutic agent interferon-alpha and the anti-viral drug ribavirin in 15 hepatitis C patients who were nonresponsive to prior therapy. The clinical study is being conducted at the Kaplan Medical Center, Israel.

Maxim also announced that it expects to commence by mid-year a clinical study to evaluate the safety of Maxamine in combination with pegylated (sustained release) interferon for the treatment of hepatitis C patients. <snip> All three studies are intended to position Maxamine for the commencement of advanced clinical studies in hepatitis C by the end of this year.

Company seemed to be saying during the recent call that they may advance into multiple PIIb/PIII HCV trials with various combinations, including PEG-INTRON.

Interesting to see how and if once a week dosing of Maxamine works out with PEG-INTRON (injection schedule for Maxamine has been matched to 3x/week interferon A schedule).

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News